Postoperative hepatocarcinoma resists the therapeutic _'s treatment recuring

Postoperative hepatocarcinoma resists the therapeutic _'s treatment recuring
Primary hepatocarcinoma is a tumour death reason of the second in our country, the high recurring rate of its effecting a radical cure postoperative excision influences the overall surgical curative effect of hepatocarcinoma seriously. Explore the postoperative therapeutic measure of recuring of hepatocarcinoma is the important subject that an effective extension patient survives for time, this kind of exploration mainly concentrates on two respects at present, the molecular mechanism of shifting that first study hepatocarcinoma and recur, have important discovery repeatly so far, form clinical target that employ extensively to treat a lot of difficulties in view of the above; Second already studied having or new function in preventing hepatocarcinoma and recuring of complex treatment measure, have practical value in improving the surgical curative effect of hepatocarcinoma in the near future.
Involve a plurality of links in view of the recurring of hepatocarcinoma, the cancer cell is infringed to have in various degree, so the measure of inhibiting hepatocarcinoma and recuring should not be single and but should have pertinence in many aspects. We have observed chemotherapy of some regional thromboembolism separately, the oral card banks up his bank, surgery of immunization therapy and portal vein cancer bolt with earth and achieves surgery and deals with the inhibitory activity that recurs after to hepatocarcinoma skill a little.
The effecting a radical cure postoperative excision of hepatocarcinoma passes the artery chemotherapy bolt of leather liver (TACE) Value so far still indeterminate. This research, to the effecting a radical cure excision patient of 823 cases of hepatocarcinoma (from October of 1996 to September of 2001) Have made the prospective observation of preventative TACE. Our result of study reveals, preventative TACE can improve hepatocarcinoma notably too postoperative overallly to have survival rate of tumour, but analyze postoperative with to have the intersection of tumour and survival rate time, indicate TACE significance function recured to inhibit like reflecting within 2 years after the operation, and two groups of patients' long term ( gt; 2 years) There is not survival rate of tumour that does not have significance difference. It is generally acknowledged hepatocarcinoma recur, more for send cancer, sow scattered originally, recur, may take place for large in the center later period relatively in the 1~2 years after the operation, so this result is like indicating it has more precise function that preventative TACE retains the trace sending cancer after excising originally and sows scatteredly, but still can't get rid of it pair " At the same time" Appear or " Heterochronism " But the inhibitory activity than the short small new born cancer of spacing interval happens.
Influence factor that hepatocarcinoma recur a lot of at the clinic, high target to endanger factor may be to some extent different in his function. So, we have compared with preventative TACE and prevented function on the recurring of hepatocarcinoma of different pathological characteristics, the result indicates to be less than or equal to 3 cm to the tumour diameter, membrane of intact bag, operation are cut to the person who greater than or equal toes 2 cm of distance of reason, the preventative TACE influence on there is no survival rate of tumouring is not prominent. In other words, hepatocarcinoma of the non- above-mentioned pathological characteristic, preventing function from having significance meanings of postoperative TACE.
Still leave a question open to the number of times that preventative TACE should implement to some extent on clinic, this research reveals TACE once postoperative singly and is superior to numerous TACE. The ones that considered numerous TACE may cause liver function to damage under the liver cirrhosis background were aggravated, so take place on the intersection of liver cirrhosis and hepatocarcinoma and excise range to be relatively little of liver, otherwise TACE of the effecting a radical cure postoperative excision is like not should not be implemented repeatedly many timesing.
Residue and invasion and attack of hiding the cancer cell of liver of position outside peripheral circulation blood and other liver may be important reasons why hepatocarcinoma recur, so this research of paying systemic chemotherapy has never been stopped to hepatocarcinoma. The foreign scholar had carried on not Fluorine of the card since middle period of 1990s, had superposed Fluorine, Fluorine iron dragon and resisted the clinical observation that recured after low dose of oral chemotherapy has been to the hepatocarcinoma skill, but not reflected the curative effect of the significance. In recent years, 5 the intersection of Fluorine and the intersection of urine and a new the intersection of forebody and the intersection of medicine and card of pyrimidine bank up the intersection of he and bank with earth, demonstrate many kinds of anticancer function of mechanism in external experiment of hepatocarcinoma, but not applied to hepatocarcinoma and resisted the clinical report that recured yet.
We choose treatment and control group at random prospectively each 15 carry on the card and bank up his bank with earth and resist the clinical observation that recured, revealed finally the recuring rate had significance differences (Plt in one year of two groups; 0.05). Volume more low to only make the radically treating excision of part to tumour at the clinic, postoperative liver function is compensated well, have HBV infect with load getting low virus, bank up card with earth the intersection of he and the intersection of bank and oral chemotherapy as prevent from effective measure that recur. But if the intersection of hepatocarcinoma and pathology brief on, have, recur high to endanger factor person, like, should consider, go ahead of the rest TACE while being aforesaid, and then look at liver function and bone marrow and inhibit the state from choosing oral chemotherapy prudently.
[1] [2]Make page one
|